COSCIENS Biopharma Q2 EPS $(0.64) Down From $(0.47) YoY, Sales $2.30M Beat $1.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
AEterna Zentaris (NASDAQ:CSCI) reported a Q2 EPS of $(0.64), a 36.17% decrease from $(0.47) YoY. However, sales were $2.30M, beating the $1.10M estimate by 109.09% and increasing 64.29% YoY.
August 13, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AEterna Zentaris reported a mixed Q2 with a significant EPS loss of $(0.64), down 36.17% YoY, but sales of $2.30M beat estimates by 109.09% and increased 64.29% YoY.
The significant EPS loss indicates financial struggles, but the strong sales performance shows potential growth. The mixed results may lead to neutral short-term price movement as investors weigh the negative EPS against the positive sales beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100